Teva Pharmaceutical Industries (TEVA) Financials

$17.58 -0.57 (-3.12%)

Closing price 03:59 PM Eastern

Extended Trading

$17.60 +0.01 (+0.06%)

As of 07:56 PM Eastern

Annual Income Statements for Teva Pharmaceutical Industries

This table shows Teva Pharmaceutical Industries' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	-1,639	-559	-2,446	417	-3,990	-999	-2,399	-16,525	68	1,573
Consolidated Net Income / (Loss)	-1,959	-615	-2,499	456	-4,099	-1,000	-2,472	-16,449	311	1,597
Net Income / (Loss) Continuing Operations	-1,959	-615	-2,499	456	-4,100	-1,000	-2,472	-16,449	311	1,597
Total Pre-Tax Income	-1,284	-624	-3,163	658	-4,406	-1,265	-2,596	-18,379	824	2,352
Total Operating Income	-303	433	-2,197	1,716	-3,572	-443	-1,637	-17,484	2,154	3,352
Total Gross Profit	8,064	7,645	6,973	7,594	7,726	7,537	8,296	10,615	11,653	11,356
Total Revenue	16,544	15,846	14,925	15,878	16,659	16,887	18,271	21,853	21,903	19,652
Operating Revenue	16,544	15,846	14,925	15,878	16,659	16,887	18,271	21,853	21,903	19,652
Total Cost of Revenue	8,481	8,200	7,952	8,284	8,933	9,351	9,975	11,237	10,250	8,296
Operating Cost of Revenue	8,481	8,200	7,952	8,284	8,933	9,351	9,975	11,237	10,250	8,296
Total Operating Expenses	8,366	7,213	9,170	5,879	11,297	7,980	9,933	28,099	9,499	8,004
Selling, General & Admin Expense	1,161	1,162	1,180	1,099	1,173	1,192	1,298	1,451	1,390	1,360
Marketing Expense	2,541	2,336	2,265	2,429	2,498	2,614	2,916	3,395	3,583	3,478
Research & Development Expense	998	953	838	967	997	1,010	1,213	1,778	2,077	1,525
Other Operating Expenses / (Income)	-14	-49	-107	-98	-40	-76	-291	-1,199	-769	-166
Impairment Charge	1,531	1,050	2,400	424	6,130	1,639	5,018	20,338	2,319	1,176
Restructuring Charge	1,388	718	512	341	479	423	987	1,836	-	-
Other Special Charges / (Income)	761	1,043	2,082	717	60	1,178	-1,208	500	899	631
Total Other Income / (Expense), net	-981	-1,057	-966	-1,058	-834	-822	-959	-895	-1,330	-1,000
Other Income / (Expense), net	-981	-1,057	-966	-1,058	-834	-822	-959	-895	-1,330	-1,000
Income Tax Expense	676	-7.00	-643	211	-168	-278	-195	-1,933	521	634
Other Gains / (Losses), net	1.00	2.00	21	9.00	138	-13	-71	-3.00	8.00	-121
Net Income / (Loss) Attributable to Noncontrolling Interest	-320	-56	-53	39	-109	-2.00	-322	-184	-18	9.00
Basic Earnings per Share	($1.45)	($0.50)	($2.20)	$0.38	($3.64)	($0.91)	($2.35)	($16.26)	$0.07	$1.84
Weighted Average Basic Shares Outstanding	1.13B	1.12B	1.11B	1.10B	1.10B	1.09B	1.02B	1.02B	955M	855M
Diluted Earnings per Share	($1.45)	($0.50)	($2.20)	$0.38	($3.64)	($0.91)	($2.35)	($16.26)	$0.07	$1.82
Weighted Average Diluted Shares Outstanding	1.13B	1.12B	1.11B	1.11B	1.10B	1.09B	1.02B	1.02B	961M	1.02B
Weighted Average Basic & Diluted Shares Outstanding	1.13B	1.12B	1.11B	1.10B	1.10B	1.09B	1.02B	1.02B	1.12B	1.02B

This table shows Teva Pharmaceutical Industries' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	214	-217	-437	-846	-139	464	69	-872	-220	-1,315	56
Consolidated Net Income / (Loss)	220	-276	-390	-874	-419	467	77	-906	-253	-1,346	58
Net Income / (Loss) Continuing Operations	220	-276	-390	-874	-419	467	77	-906	-253	-1,345	58
Total Pre-Tax Income	294	-247	-324	-246	-467	506	65	-923	-272	-1,198	166
Total Operating Income	519	-29	-51	-5.00	-218	755	345	-654	-13	-954	419
Total Gross Profit	1,877	2,121	2,148	2,024	1,771	2,416	1,851	1,796	1,582	1,770	1,669
Total Revenue	3,891	4,229	4,332	4,164	3,819	4,457	3,850	3,878	3,661	3,883	3,595
Operating Revenue	3,891	4,229	4,332	4,164	3,819	4,457	3,850	3,878	3,661	3,883	3,595
Total Cost of Revenue	2,014	2,110	2,183	2,140	2,048	2,040	1,999	2,082	2,079	2,113	1,926
Operating Cost of Revenue	2,014	2,110	2,183	2,140	2,048	2,040	1,999	2,082	2,079	2,113	1,926
Total Operating Expenses	1,356	2,150	2,198	2,030	1,988	1,662	1,506	2,450	1,595	2,722	1,250
Selling, General & Admin Expense	297	302	298	283	278	291	268	307	296	288	283
Marketing Expense	622	651	626	656	608	611	576	603	546	548	539
Research & Development Expense	247	247	240	269	242	226	253	240	234	210	175
Other Operating Expenses / (Income)	5.00	8.00	-21	-2.00	1.00	-5.00	-9.00	-33	-2.00	-19	-2.00
Impairment Charge	121	362	628	461	80	5.00	104	763	178	1,431	24
Restructuring Charge	-22	458	-23	280	673	-	-	108	110	230	36
Other Special Charges / (Income)	86	122	450	83	106	34	314	462	233	34	195
Total Other Income / (Expense), net	-225	-218	-272	-241	-250	-249	-280	-268	-260	-245	-252
Other Income / (Expense), net	-225	-218	-272	-241	-250	-249	-280	-268	-260	-245	-252
Income Tax Expense	74	29	69	630	-52	40	-12	-16	-19	148	107
Other Gains / (Losses), net	0.00	-	3.00	2.00	-4.00	1.00	0.00	1.00	0.00	1.00	-1.00
Net Income / (Loss) Attributable to Noncontrolling Interest	6.00	-58	47	-29	-280	4.00	8.00	-35	-33	-32	3.00
Basic Earnings per Share	$0.19	($0.19)	($0.39)	($0.75)	($0.12)	$0.42	$0.06	($0.78)	($0.20)	($1.18)	$0.05
Weighted Average Basic Shares Outstanding	1.14B	1.13B	1.13B	1.13B	1.12B	1.12B	1.12B	1.12B	1.12B	1.11B	1.11B
Diluted Earnings per Share	$0.18	($0.19)	($0.39)	($0.75)	($0.12)	$0.42	$0.06	($0.78)	($0.20)	($1.18)	$0.05
Weighted Average Diluted Shares Outstanding	1.16B	1.13B	1.13B	1.13B	1.12B	1.12B	1.14B	1.12B	1.12B	1.11B	1.12B
Weighted Average Basic & Diluted Shares Outstanding	1.15B	1.13B	1.13B	1.13B	1.13B	1.12B	1.12B	1.12B	1.12B	1.11B	1.11B

This table details how cash moves in and out of Teva Pharmaceutical Industries' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	74	393	636	1,850	202	1,073	4,607	-25	-5,958	4,720
Net Cash From Operating Activities	1,247	1,368	1,590	798	1,216	748	2,446	2,225	3,890	5,542
Net Cash From Continuing Operating Activities	1,247	1,368	1,590	2,499	1,216	1,644	6,092	2,225	3,890	5,542
Net Income / (Loss) Continuing Operations	-1,959	-615	-2,499	456	-4,099	-1,000	-2,472	-16,449	311	1,597
Consolidated Net Income / (Loss)	-1,959	-615	-2,499	456	-4,099	-1,000	-2,472	-16,449	311	1,597
Depreciation Expense	1,059	1,153	1,308	1,330	1,557	1,722	1,842	2,112	1,524	1,308
Non-Cash Adjustments To Reconcile Net Income	2,656	1,158	2,581	1,391	6,542	2,273	3,960	20,525	2,170	1,287
Changes in Operating Assets and Liabilities, net	-509	-328	200	-678	-2,784	-1,351	-884	-3,963	-115	1,350
Net Cash From Investing Activities	792	968	656	1,523	863	1,355	1,866	3,446	-34,405	-5,565
Net Cash From Continuing Investing Activities	792	968	656	1,523	863	1,355	1,866	3,446	-34,405	-5,565
Purchase of Property, Plant & Equipment	-498	-526	-548	-562	-578	-525	-651	-874	-901	-772
Acquisitions	-15	0.00	-7.00	0.00	0.00	-	-	-	-36,148	-3,309
Purchase of Investments	-71	-46	-1.00	-47	-55	-8.00	-119	-200	-481	-2,003
Divestitures	43	68	68	311	67	343	-	43	-	-
Sale and/or Maturity of Investments	40	0.00	4.00	172	12	2.00	890	3,477	2,002	524
Other Investing Activities, net	1,293	1,472	1,140	1,649	1,417	1,543	1,746	1,000	1,123	-5.00
Net Cash From Financing Activities	-1,791	-1,913	-1,487	-2,172	-1,885	-1,926	-3,351	-5,750	25,217	4,805
Net Cash From Continuing Financing Activities	-1,791	-1,913	-1,487	-2,172	-1,885	-1,926	-3,351	-5,750	25,217	4,805
Repayment of Debt	-1,649	-5,064	-1,487	-2,381	-2,435	-2,374	-7,763	-5,057	-1,168	-2,699
Payment of Dividends	-78	0.00	0.00	-	-	-52	-22	-1,199	-1,558	-1,155
Issuance of Debt	0.00	3,151	0.00	700	550	500	4,434	506	27,250	2,128
Other Financing Activities, net	-64	0.00	0.00	-491	-	0.00	-	-	35	388
Other Net Changes in Cash	-174	-30	-123	-	8.00	-	-	54	-660	-
Cash Interest Paid	1,004	1,078	948	913	846	840	815	795	290	243
Cash Income Taxes Paid	471	298	543	495	709	552	420	106	341	802

This table details how cash moves in and out of Teva Pharmaceutical Industries' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-1,603	-18	1,061	-733	-236	977	-420	494	-658	576	167
Net Cash From Operating Activities	-105	575	693	103	-124	1,184	5.00	324	-145	973	543
Net Cash From Continuing Operating Activities	-105	575	693	103	-124	1,184	5.00	324	-145	973	543
Net Income / (Loss) Continuing Operations	220	-275	-390	-875	-419	467	77	-906	-253	-1,347	59
Consolidated Net Income / (Loss)	220	-275	-390	-875	-419	467	77	-906	-253	-1,347	59
Depreciation Expense	244	269	259	259	272	266	283	300	304	306	321
Non-Cash Adjustments To Reconcile Net Income	111	831	557	561	707	84	76	773	225	1,490	65
Changes in Operating Assets and Liabilities, net	-680	-250	267	158	-684	367	-431	157	-421	524	98
Net Cash From Investing Activities	201	202	268	178	144	301	184	302	181	168	147
Net Cash From Continuing Investing Activities	201	202	268	178	144	301	184	302	181	168	147
Purchase of Property, Plant & Equipment	-127	-129	-148	-97	-124	-119	-149	-119	-139	-142	-122
Acquisitions	0.00	-	-	-	-	-	-	-	-	-	-
Purchase of Investments	-11	-15	-1.00	-43	-12	-2.00	-38	-2.00	-4.00	1.00	2.00
Divestitures	17	19	38	1.00	-15	-	10	56	2.00	23	2.00
Other Investing Activities, net	322	342	339	317	295	422	361	367	322	282	268
Net Cash From Financing Activities	-1,744	-674	-	-966	-151	-576	-576	-55	-706	-711	-440
Net Cash From Continuing Financing Activities	-1,743	-674	-	-966	-151	-576	-576	-55	-706	-711	-440
Repayment of Debt	-1,365	-674	-	-966	-9.00	-576	-1,276	-55	-3,157	-711	-440
Payment of Dividends	-340	-	-	-	-78	-	-	-	0.00	-	-
Other Financing Activities, net	-38	-	-	-	-64	-	-	-	0.00	-	-
Other Net Changes in Cash	45	-121	100	-49	-104	68	-33	-77	12	146	-84

This table presents Teva Pharmaceutical Industries' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	39,326	43,479	44,011	47,666	50,640	57,470	60,683	70,615	93,057	54,233
Total Current Assets	12,552	12,485	12,051	12,573	13,005	13,464	13,794	15,382	17,228	18,398
Cash & Equivalents	3,300	3,226	2,801	2,165	2,177	1,975	1,782	963	988	6,946
Accounts Receivable	3,059	3,408	3,696	4,529	4,581	5,676	5,822	7,128	7,523	5,350
Inventories, net	3,007	4,021	3,833	3,818	4,403	4,422	4,731	4,924	4,954	3,966
Prepaid Expenses	1,006	1,255	1,162	1,075	945	870	899	1,100	1,629	910
Other Current Assets	409	504	549	965	710	434	468	701	2,134	491
Other Current Nonoperating Assets	1,771	70	10	19	189	87	92	566	-	-
Plant, Property, & Equipment, net	4,581	5,750	5,739	5,982	6,296	6,436	6,868	7,673	8,073	6,544
Total Noncurrent Assets	22,193	25,243	26,221	29,112	31,339	37,569	40,021	47,560	67,756	29,291
Goodwill	15,147	17,177	17,633	20,040	20,624	24,846	24,917	28,414	44,409	19,025
Intangible Assets	4,418	5,387	6,270	7,466	8,923	11,232	14,005	17,640	21,487	7,675
Noncurrent Deferred & Refundable Income Taxes	1,799	1,812	1,458	596	695	386	368	574	625	250
Other Noncurrent Operating Assets	829	867	860	1,010	1,097	1,105	731	932	1,235	2,341
Total Liabilities & Shareholders' Equity	39,326	43,479	44,011	47,666	50,640	57,470	60,683	70,615	93,057	54,233
Total Liabilities	33,606	35,353	35,413	36,422	39,579	42,407	44,889	51,870	58,064	24,306
Total Current Liabilities	12,796	12,247	11,469	11,027	13,164	13,674	14,322	17,921	18,488	13,005
Short-Term Debt	1,781	1,672	2,109	1,426	3,188	2,345	2,216	3,646	3,276	1,585
Accounts Payable	2,203	2,602	1,887	1,686	1,756	1,718	1,853	2,069	2,157	1,918
Accrued Expenses	2,792	2,771	2,151	2,208	1,780	1,869	1,868	3,014	3,405	1,681
Current Employee Benefit Liabilities	624	611	566	563	685	693	870	549	-	-
Other Current Liabilities	4,698	4,579	4,755	5,144	5,757	7,048	7,515	8,605	9,534	7,821
Other Current Nonoperating Liabilities	698	13	-	-	-	-	-	38	116	0.00
Total Noncurrent Liabilities	20,809	23,106	23,944	25,395	26,414	28,733	30,567	33,949	39,576	11,301
Long-Term Debt	16,002	18,161	19,103	21,617	22,731	24,562	26,700	28,829	32,524	8,358
Noncurrent Deferred & Payable Income Tax Liabilities	483	606	548	784	964	1,096	2,140	3,277	5,413	1,748
Other Noncurrent Operating Liabilities	4,324	4,339	4,294	2,994	2,719	3,075	1,727	1,843	1,639	1,195
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Redeemable Noncontrolling Interest	340	0.00	-	-	-	-	-	-	-	-
Total Equity & Noncontrolling Interests	5,380	8,126	8,598	11,244	11,061	15,063	15,794	18,745	34,993	29,927
Total Preferred & Common Equity	5,373	7,506	7,804	10,278	10,026	13,972	14,707	17,359	33,337	29,769
Total Common Equity	5,373	7,505	7,804	10,278	10,027	13,972	14,707	13,728	29,717	26,478
Common Stock	27,822	27,864	27,745	27,618	27,500	27,368	27,266	23,533	23,463	17,809
Retained Earnings	-15,173	-13,534	-12,975	-10,529	-10,946	-6,956	-5,958	-3,803	13,607	14,851
Treasury Stock	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128	-4,142	-4,149	-4,194	-4,227
Accumulated Other Comprehensive Income / (Loss)	-3,148	-2,697	-2,838	-2,683	-2,399	-2,312	-2,459	-1,853	-3,159	-1,955
Noncontrolling Interest	7.00	620	794	966	1,035	1,091	1,087	1,386	1,656	158

This table presents Teva Pharmaceutical Industries' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	38,415	41,758	41,338	42,773	42,088	43,095	43,456	44,252
Total Current Assets	11,528	12,314	11,632	12,297	11,425	12,088	11,501	11,453
Cash & Equivalents	1,697	3,319	2,258	2,991	2,249	2,669	2,143	2,225
Accounts Receivable	3,384	3,462	3,766	3,456	3,385	3,539	3,435	3,730
Inventories, net	3,247	3,959	3,927	3,949	4,051	4,109	4,118	3,859
Prepaid Expenses	1,018	1,127	1,096	1,336	1,168	1,228	1,253	1,045
Other Current Assets	368	445	517	495	520	486	542	579
Other Current Nonoperating Assets	1,814	2.00	69	70	51	56	10	16
Plant, Property, & Equipment, net	4,631	5,672	5,573	5,618	5,622	5,712	5,751	5,568
Total Noncurrent Assets	22,255	23,773	24,133	24,857	25,041	25,295	26,205	27,232
Goodwill	15,477	16,124	16,488	17,007	16,885	17,118	17,799	18,433
Intangible Assets	4,189	4,756	4,853	5,056	5,525	5,738	5,964	6,393
Noncurrent Deferred & Refundable Income Taxes	1,762	2,070	2,000	1,960	1,748	1,578	1,572	1,546
Other Noncurrent Operating Assets	827	823	792	834	883	861	870	860
Total Liabilities & Shareholders' Equity	38,415	41,758	41,338	42,773	42,088	43,095	43,456	44,252
Total Liabilities	32,146	35,375	34,774	35,230	34,576	35,387	34,844	34,734
Total Current Liabilities	11,157	13,797	13,037	13,792	11,394	11,843	10,411	11,534
Short-Term Debt	421	2,580	2,094	3,060	1,479	1,980	1,023	2,769
Accounts Payable	2,290	2,371	2,366	2,439	2,280	2,508	2,381	1,635
Accrued Expenses	2,952	2,984	2,840	2,784	2,741	2,498	2,267	2,041
Current Employee Benefit Liabilities	474	619	492	492	530	451	432	496
Other Current Liabilities	4,660	5,026	4,891	4,755	4,362	4,406	4,309	4,593
Other Current Nonoperating Liabilities	358	216	356	262	-	-	-	-
Total Noncurrent Liabilities	20,990	21,578	21,737	21,438	23,182	23,543	24,433	23,200
Long-Term Debt	16,230	16,400	16,547	16,584	18,495	18,698	19,668	18,497
Noncurrent Deferred & Payable Income Tax Liabilities	461	538	553	569	544	534	550	503
Other Noncurrent Operating Liabilities	4,299	4,639	4,637	4,285	4,142	4,311	4,214	4,200
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	0.00	-	-	-	-	-	-	-
Total Equity & Noncontrolling Interests	6,269	6,383	6,563	7,543	7,512	7,708	8,612	9,519
Total Preferred & Common Equity	6,262	6,065	6,359	7,278	6,929	7,052	7,860	8,767
Total Common Equity	6,262	6,065	6,359	7,278	6,929	7,050	7,861	8,768
Common Stock	28,023	27,918	27,887	27,854	27,837	27,805	27,776	27,709
Retained Earnings	-14,958	-14,956	-14,519	-13,673	-13,870	-13,950	-13,086	-11,660
Treasury Stock	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128
Accumulated Other Comprehensive Income / (Loss)	-2,675	-2,769	-2,881	-2,775	-2,910	-2,677	-2,701	-3,153
Noncontrolling Interest	7.00	319	204	265	582	656	751	751

This table displays calculated financial ratios and metrics derived from Teva Pharmaceutical Industries' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	4.40%	6.17%	-6.00%	-4.69%	-1.35%	-7.57%	-16.39%	-0.23%	11.45%	-3.06%
EBITDA Growth	-142.53%	128.52%	-193.31%	169.78%	-723.41%	160.61%	95.36%	-792.80%	-35.85%	-28.88%
EBIT Growth	-105.77%	80.27%	-580.70%	114.93%	-248.30%	51.27%	85.88%	-2,330.46%	-64.97%	-35.35%
NOPAT Growth	-169.98%	119.71%	-231.93%	146.62%	-706.32%	72.94%	90.64%	-1,645.18%	-67.65%	-26.01%
Net Income Growth	-218.54%	75.39%	-648.03%	111.12%	-309.90%	59.55%	84.97%	-5,389.07%	-80.53%	-47.50%
EPS Growth	-190.00%	77.27%	-678.95%	110.44%	-300.00%	61.28%	85.55%	-23,328.57%	-96.15%	-48.88%
Operating Cash Flow Growth	-8.85%	-13.96%	99.25%	-34.38%	62.57%	-69.42%	9.93%	-42.80%	-29.81%	8.09%
Free Cash Flow Firm Growth	102.73%	-26.25%	-3.04%	31.57%	6.75%	-54.45%	-27.74%	121.97%	-3,792.71%	-82.62%
Invested Capital Growth	-22.46%	-8.62%	-15.90%	-7.25%	-13.27%	-6.84%	-13.86%	-28.88%	112.37%	4.67%
Revenue Q/Q Growth	-1.36%	3.76%	-1.43%	-2.19%	-0.08%	3.00%	-4.64%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-142.86%	146.57%	-126.77%	-16.26%	5.10%	115.62%	92.77%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	-141.81%	73.21%	-47.80%	-32.09%	3.80%	72.58%	79.09%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	-162.99%	133.93%	-88.42%	-26.71%	6.71%	88.20%	85.75%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	-61.10%	74.67%	-91.49%	-40.70%	2.06%	76.84%	77.44%	0.00%	0.00%	0.00%
EPS Q/Q Growth	-72.62%	76.19%	-89.66%	-42.42%	0.82%	76.61%	78.42%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-32.81%	18.24%	48.18%	18.57%	-14.55%	29.64%	-16.75%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	63.31%	6.71%	-5.38%	34.51%	-23.56%	-23.69%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-14.06%	-2.04%	-5.42%	-3.10%	1.00%	-1.72%	-8.21%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	48.74%	48.25%	46.72%	47.83%	46.38%	44.63%	45.41%	48.57%	53.20%	57.79%
EBITDA Margin	-1.36%	3.34%	-12.43%	12.52%	-17.10%	2.71%	-4.13%	-74.44%	10.72%	18.62%
Operating Margin	-1.83%	2.73%	-14.72%	10.81%	-21.44%	-2.62%	-8.96%	-80.01%	9.83%	17.06%
EBIT Margin	-7.76%	-3.94%	-21.19%	4.14%	-26.45%	-7.49%	-14.21%	-84.10%	3.76%	11.97%
Profit (Net Income) Margin	-11.84%	-3.88%	-16.74%	2.87%	-24.61%	-5.92%	-13.53%	-75.27%	1.42%	8.13%
Tax Burden Percent	152.57%	98.56%	79.01%	69.30%	93.03%	79.05%	95.22%	89.50%	37.74%	67.90%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	32.07%	0.00%	0.00%	0.00%	0.00%	63.23%	26.96%
Return on Invested Capital (ROIC)	-0.97%	1.17%	-5.20%	3.49%	-6.71%	-0.75%	-2.48%	-20.46%	1.54%	7.61%
ROIC Less NNEP Spread (ROIC-NNEP)	-12.63%	-4.08%	-10.10%	0.30%	-13.32%	-3.41%	-7.05%	-33.23%	-1.00%	-7.74%
Return on Net Nonoperating Assets (RNNOA)	-27.33%	-8.53%	-19.98%	0.59%	-24.67%	-5.73%	-11.84%	-40.76%	-0.58%	-1.61%
Return on Equity (ROE)	-28.30%	-7.35%	-25.19%	4.09%	-31.38%	-6.48%	-14.31%	-61.22%	0.96%	5.99%
Cash Return on Invested Capital (CROIC)	24.34%	10.18%	12.06%	11.02%	7.50%	6.33%	12.42%	13.29%	-70.41%	3.05%
Operating Return on Assets (OROA)	-3.10%	-1.43%	-6.90%	1.34%	-8.15%	-2.14%	-3.95%	-22.46%	1.12%	4.67%
Return on Assets (ROA)	-4.73%	-1.41%	-5.45%	0.93%	-7.58%	-1.69%	-3.77%	-20.10%	0.42%	3.17%
Return on Common Equity (ROCE)	-26.32%	-6.73%	-22.95%	3.72%	-28.83%	-6.02%	-11.78%	-49.49%	0.83%	5.60%
Return on Equity Simple (ROE_SIMPLE)	-36.46%	-8.19%	-32.02%	4.44%	-40.88%	-7.16%	-16.81%	-94.76%	0.93%	5.36%
Net Operating Profit after Tax (NOPAT)	-212	303	-1,538	1,166	-2,500	-310	-1,146	-12,239	792	2,448
NOPAT Margin	-1.28%	1.91%	-10.30%	7.34%	-15.01%	-1.84%	-6.27%	-56.01%	3.62%	12.46%
Net Nonoperating Expense Percent (NNEP)	11.66%	5.25%	4.90%	3.20%	6.61%	2.66%	4.57%	12.78%	2.54%	15.34%
Return On Investment Capital (ROIC_SIMPLE)	-0.92%	1.08%	-5.16%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	51.26%	51.75%	53.28%	52.17%	53.62%	55.37%	54.59%	51.42%	46.80%	42.21%
SG&A Expenses to Revenue	7.02%	7.33%	7.91%	6.92%	7.04%	7.06%	7.10%	6.64%	6.35%	6.92%
R&D to Revenue	6.03%	6.01%	5.61%	6.09%	5.98%	5.98%	6.64%	8.14%	9.48%	7.76%
Operating Expenses to Revenue	50.57%	45.52%	61.44%	37.03%	67.81%	47.26%	54.36%	128.58%	43.37%	40.73%
Earnings before Interest and Taxes (EBIT)	-1,284	-624	-3,163	658	-4,406	-1,265	-2,596	-18,379	824	2,352
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-225	529	-1,855	1,988	-2,849	457	-754	-16,267	2,348	3,660
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.65	1.56	1.30	0.86	1.05	0.77	1.07	1.55	1.20	2.23
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.51	0.74	0.68	0.56	0.63	0.63	0.86	0.97	1.63	3.00
Price to Earnings (P/E)	0.00	0.00	0.00	21.19	0.00	0.00	0.00	0.00	523.92	37.54
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4.49%	3.88%	2.21%
Earnings Yield	0.00%	0.00%	0.00%	4.72%	0.00%	0.00%	0.00%	0.00%	0.19%	2.66%
Enterprise Value to Invested Capital (EV/IC)	2.08	1.17	1.09	0.96	1.02	0.92	1.03	1.16	1.08	1.99
Enterprise Value to Revenue (EV/Rev)	2.41	1.83	1.97	1.93	2.12	2.17	2.40	2.65	3.46	3.33
Enterprise Value to EBITDA (EV/EBITDA)	0.00	54.69	0.00	15.43	0.00	80.36	0.00	0.00	32.25	17.89
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	46.62	0.00	0.00	0.00	0.00	91.89	27.85
Enterprise Value to NOPAT (EV/NOPAT)	0.00	95.45	0.00	26.32	0.00	0.00	0.00	0.00	95.59	26.75
Enterprise Value to Operating Cash Flow (EV/OCF)	31.92	21.15	18.45	38.45	29.07	49.10	17.96	25.98	19.46	11.82
Enterprise Value to Free Cash Flow (EV/FCFF)	7.47	11.00	8.23	8.34	12.65	14.03	7.64	7.27	0.00	66.80
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	3.11	2.44	2.47	2.05	2.34	1.79	1.83	1.73	1.02	0.33
Long-Term Debt to Equity	2.80	2.23	2.22	1.92	2.06	1.63	1.69	1.54	0.93	0.28
Financial Leverage	2.16	2.09	1.98	1.99	1.85	1.68	1.68	1.23	0.58	0.21
Leverage Ratio	5.98	5.23	4.62	4.41	4.14	3.83	3.80	3.05	2.27	1.89
Compound Leverage Factor	5.98	5.23	4.62	4.41	4.14	3.83	3.80	3.05	2.27	1.89
Debt to Total Capital	75.66%	70.94%	71.16%	67.21%	70.09%	64.11%	64.67%	63.40%	50.57%	24.94%
Short-Term Debt to Total Capital	7.58%	5.98%	7.07%	4.16%	8.62%	5.59%	4.96%	7.12%	4.63%	3.98%
Long-Term Debt to Total Capital	68.08%	64.96%	64.08%	63.05%	61.47%	58.52%	59.72%	56.28%	45.94%	20.96%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	7.09%	5.11%	8.25%
Noncontrolling Interests to Total Capital	1.48%	2.22%	2.66%	2.82%	2.80%	2.60%	2.43%	2.71%	2.34%	0.40%
Common Equity to Total Capital	22.86%	26.84%	26.18%	29.98%	27.11%	33.29%	32.89%	26.80%	41.98%	66.41%
Debt to EBITDA	-79.04	37.49	-11.44	11.59	-9.10	58.88	-38.35	-2.00	15.25	2.72
Net Debt to EBITDA	-64.37	31.39	-9.93	10.50	-8.33	54.56	-35.99	-1.94	14.83	0.82
Long-Term Debt to EBITDA	-71.12	34.33	-10.30	10.87	-7.98	53.75	-35.41	-1.77	13.85	2.28
Debt to NOPAT	-83.84	65.43	-13.79	19.77	-10.37	-86.77	-25.23	-2.65	45.20	4.06
Net Debt to NOPAT	-68.28	54.79	-11.97	17.91	-9.50	-80.40	-23.68	-2.57	43.95	1.22
Long-Term Debt to NOPAT	-75.45	59.92	-12.42	18.54	-9.09	-79.21	-23.30	-2.36	41.06	3.41
Altman Z-Score	0.21	0.09	-0.12	0.25	-0.10	0.20	0.22	-0.42	0.82	2.47
Noncontrolling Interest Sharing Ratio	6.99%	8.46%	8.87%	8.97%	8.13%	7.06%	17.67%	19.15%	13.44%	6.55%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.98	1.02	1.05	1.14	0.99	0.98	0.96	0.86	0.93	1.41
Quick Ratio	0.50	0.54	0.57	0.61	0.51	0.56	0.53	0.45	0.46	0.95
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	5,330	2,629	3,565	3,677	2,795	2,618	5,747	7,953	-36,205	980
Operating Cash Flow to CapEx	250.40%	260.08%	290.15%	141.99%	210.38%	142.48%	375.73%	254.58%	431.74%	717.88%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.40	0.36	0.33	0.32	0.31	0.29	0.28	0.27	0.30	0.39
Accounts Receivable Turnover	5.12	4.46	3.63	3.49	3.25	2.94	2.82	2.98	3.40	3.65
Inventory Turnover	2.41	2.09	2.08	2.02	2.02	2.04	2.07	2.28	2.30	1.99
Fixed Asset Turnover	3.20	2.76	2.55	2.59	2.62	2.54	2.51	2.78	3.00	3.01
Accounts Payable Turnover	3.53	3.65	4.45	4.81	5.14	5.24	5.09	5.32	5.03	3.26
Days Sales Outstanding (DSO)	71.34	81.82	100.57	104.71	112.37	124.26	129.35	122.35	107.26	99.91
Days Inventory Outstanding (DIO)	151.23	174.80	175.59	181.11	180.29	178.64	176.65	160.43	158.82	183.40
Days Payable Outstanding (DPO)	103.40	99.91	82.00	75.83	70.97	69.69	71.76	68.63	72.55	111.95
Cash Conversion Cycle (CCC)	119.17	156.71	194.16	209.99	221.69	233.20	234.24	214.15	193.52	171.36
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	19,131	24,673	26,999	32,102	34,613	39,908	42,836	49,729	69,921	32,924
Invested Capital Turnover	0.76	0.61	0.51	0.48	0.45	0.41	0.39	0.37	0.43	0.61
Increase / (Decrease) in Invested Capital	-5,542	-2,326	-5,103	-2,511	-5,295	-2,928	-6,893	-20,192	36,997	1,468
Enterprise Value (EV)	39,802	28,930	29,334	30,679	35,353	36,725	43,930	57,801	75,714	65,494
Market Capitalization	24,972	11,703	10,129	8,835	10,576	10,702	15,709	21,272	35,626	59,048
Book Value per Share	$4.74	$6.70	$7.03	$9.32	$9.15	$12.79	$14.44	$12.23	$29.25	$27.68
Tangible Book Value per Share	($12.53)	($13.43)	($14.50)	($15.62)	($17.81)	($20.24)	($23.77)	($28.80)	($35.61)	($0.23)
Total Capital	23,503	27,959	29,810	34,287	36,980	41,970	44,710	51,220	70,793	39,870
Total Debt	17,783	19,833	21,212	23,043	25,919	26,907	28,916	32,475	35,800	9,943
Total Long-Term Debt	16,002	18,161	19,103	21,617	22,731	24,562	26,700	28,829	32,524	8,358
Net Debt	14,483	16,607	18,411	20,878	23,742	24,932	27,134	31,512	34,812	2,997
Capital Expenditures (CapEx)	498	526	548	562	578	525	651	874	901	772
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1,763	-1,316	-110	807	852	160	-94	144	1,028	32
Debt-free Net Working Capital (DFNWC)	1,537	1,910	2,691	2,972	3,029	2,135	1,688	1,107	2,016	6,978
Net Working Capital (NWC)	-244	238	582	1,546	-159	-210	-528	-2,539	-1,260	5,393
Net Nonoperating Expense (NNE)	1,747	918	961	710	1,599	690	1,326	4,210	481	851
Net Nonoperating Obligations (NNO)	13,411	16,547	18,401	20,858	23,552	24,845	27,042	30,984	34,928	2,997
Total Depreciation and Amortization (D&A)	1,059	1,153	1,308	1,330	1,557	1,722	1,842	2,112	1,524	1,308
Debt-free, Cash-free Net Working Capital to Revenue	-10.66%	-8.30%	-0.74%	5.08%	5.11%	0.95%	-0.51%	0.66%	4.69%	0.16%
Debt-free Net Working Capital to Revenue	9.29%	12.05%	18.03%	18.72%	18.18%	12.64%	9.24%	5.07%	9.20%	35.51%
Net Working Capital to Revenue	-1.47%	1.50%	3.90%	9.74%	-0.95%	-1.24%	-2.89%	-11.62%	-5.75%	27.44%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.45)	($0.50)	($2.12)	$0.38	($3.64)	($0.91)	($2.35)	($16.26)	$0.00	$1.84
Adjusted Weighted Average Basic Shares Outstanding	1.13B	1.12B	1.11B	1.10B	1.10B	1.09B	1.02B	1.02B	0.00	855M
Adjusted Diluted Earnings per Share	($1.45)	($0.50)	($2.12)	$0.38	($3.64)	($0.91)	($2.35)	($16.26)	$0.00	$1.82
Adjusted Weighted Average Diluted Shares Outstanding	1.13B	1.12B	1.11B	1.11B	1.10B	1.09B	1.02B	1.12B	0.00	1.02B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.13B	1.12B	1.11B	1.10B	1.10B	1.09B	1.09B	1.12B	0.00	1.02B
Normalized Net Operating Profit after Tax (NOPAT)	2,364	2,271	1,958	2,173	2,168	1,958	2,212	3,633	3,760	3,768
Normalized NOPAT Margin	14.29%	14.33%	13.12%	13.68%	13.01%	11.59%	12.11%	16.62%	17.17%	19.18%
Pre Tax Income Margin	-7.76%	-3.94%	-21.19%	4.14%	-26.45%	-7.49%	-14.21%	-84.10%	3.76%	11.97%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-3.98%	0.00%	0.00%	0.00%	0.00%	-5.20%	-0.89%	-7.29%	500.96%	72.32%
Augmented Payout Ratio	-3.98%	0.00%	0.00%	0.00%	0.00%	-5.20%	-0.89%	-7.29%	500.96%	99.81%

This table displays calculated financial ratios and metrics derived from Teva Pharmaceutical Industries' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	1.89%	-5.12%	12.52%	7.37%	4.32%	14.78%	7.09%	2.43%	0.00%	-5.27%	-7.51%
EBITDA Growth	374.49%	-97.15%	-118.39%	102.09%	-732.26%	186.45%	-28.69%	22.44%	104.78%	-720.14%	-31.36%
EBIT Growth	162.82%	-148.81%	-596.92%	73.32%	-71.43%	142.20%	-61.08%	20.52%	71.88%	-581.25%	-56.28%
NOPAT Growth	354.50%	-102.92%	-108.74%	99.24%	-1,576.92%	204.12%	174.43%	31.09%	98.18%	-1,338.96%	-70.16%
Net Income Growth	152.51%	-159.10%	-606.49%	3.53%	-65.61%	134.70%	32.76%	-249.81%	73.42%	-785.53%	-80.79%
EPS Growth	250.00%	-145.24%	-750.00%	3.85%	40.00%	135.59%	20.00%	-271.43%	76.74%	-742.86%	-80.77%
Operating Cash Flow Growth	15.32%	-51.44%	13,760.00%	-68.21%	14.48%	21.69%	-99.08%	163.41%	-195.92%	113.38%	2.65%
Free Cash Flow Firm Growth	91.79%	82.76%	-23.22%	-34.78%	-31.76%	-31.88%	-20.44%	6.86%	44.69%	72.92%	188.23%
Invested Capital Growth	-18.94%	-22.46%	-11.62%	-9.46%	-10.18%	-8.62%	-11.76%	-13.99%	-12.38%	-15.90%	-13.84%
Revenue Q/Q Growth	-7.99%	-2.38%	4.03%	9.03%	-14.31%	15.77%	-0.72%	5.93%	-5.72%	8.01%	-5.04%
EBITDA Q/Q Growth	2,345.45%	134.38%	-592.31%	106.63%	-126.52%	121.84%	155.95%	-2,106.45%	103.47%	-282.99%	160.85%
EBIT Q/Q Growth	219.03%	23.53%	-31.30%	47.44%	-198.94%	678.46%	107.05%	-237.73%	77.23%	-817.96%	114.40%
NOPAT Q/Q Growth	2,013.14%	43.14%	-920.00%	97.71%	-123.09%	70.13%	189.27%	-4,930.77%	98.64%	-548.42%	122.42%
Net Income Q/Q Growth	179.71%	29.23%	55.38%	-108.59%	-196.77%	506.49%	108.50%	-258.10%	81.20%	-2,420.69%	122.39%
EPS Q/Q Growth	194.74%	51.28%	48.00%	-525.00%	-131.58%	600.00%	107.69%	-290.00%	83.05%	-2,460.00%	123.81%
Operating Cash Flow Q/Q Growth	-118.26%	-17.03%	572.82%	183.06%	-110.47%	23,580.00%	-98.46%	323.45%	-114.90%	79.19%	341.46%
Free Cash Flow Firm Q/Q Growth	-9.30%	90.98%	19.25%	-7.16%	-12.92%	-19.77%	1.30%	-2.87%	-13.72%	-6.29%	36.05%
Invested Capital Q/Q Growth	3.32%	-14.06%	-4.18%	-4.73%	-1.11%	-2.04%	-1.84%	-5.49%	0.56%	-5.42%	-4.33%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	48.24%	50.15%	49.58%	48.61%	46.37%	54.21%	48.08%	46.31%	43.21%	45.58%	46.43%
EBITDA Margin	13.83%	0.52%	-1.48%	0.31%	-5.13%	17.32%	9.04%	-16.04%	0.85%	-23.00%	13.57%
Operating Margin	13.34%	-0.69%	-1.18%	-0.12%	-5.71%	16.94%	8.96%	-16.86%	-0.36%	-24.57%	11.66%
EBIT Margin	7.56%	-5.84%	-7.46%	-5.91%	-12.25%	11.35%	1.69%	-23.78%	-7.46%	-30.88%	4.65%
Profit (Net Income) Margin	5.65%	-6.53%	-9.00%	-20.99%	-10.97%	10.48%	2.00%	-23.36%	-6.91%	-34.66%	1.61%
Tax Burden Percent	74.83%	111.74%	120.37%	355.28%	89.72%	92.29%	118.46%	98.16%	93.01%	112.35%	34.94%
Interest Burden Percent	100.00%	100.00%	100.31%	100.00%	99.79%	100.00%	100.00%	100.11%	99.63%	99.92%	99.40%
Effective Tax Rate	25.17%	0.00%	0.00%	0.00%	0.00%	7.91%	-18.46%	0.00%	0.00%	0.00%	64.46%
Return on Invested Capital (ROIC)	7.51%	-0.36%	-0.58%	-0.06%	-2.48%	9.57%	6.03%	-6.39%	-0.13%	-8.69%	2.03%
ROIC Less NNEP Spread (ROIC-NNEP)	6.40%	-2.07%	-2.69%	-5.08%	-3.99%	8.26%	4.23%	-8.75%	-1.37%	-12.14%	1.59%
Return on Net Nonoperating Assets (RNNOA)	14.06%	-4.48%	-6.51%	-12.34%	-8.73%	17.26%	9.11%	-18.94%	-2.85%	-24.02%	3.08%
Return on Equity (ROE)	21.58%	-4.84%	-7.09%	-12.39%	-11.22%	26.83%	15.14%	-25.33%	-2.98%	-32.71%	5.11%
Cash Return on Invested Capital (CROIC)	22.30%	24.34%	13.76%	12.44%	11.35%	10.18%	9.17%	12.01%	9.59%	12.06%	12.22%
Operating Return on Assets (OROA)	3.09%	-2.33%	-2.98%	-2.28%	-4.55%	4.11%	0.60%	-8.02%	-2.46%	-10.05%	1.53%
Return on Assets (ROA)	2.31%	-2.61%	-3.60%	-8.10%	-4.07%	3.80%	0.71%	-7.88%	-2.28%	-11.29%	0.53%
Return on Common Equity (ROCE)	21.15%	-4.50%	-6.63%	-11.64%	-10.51%	24.56%	13.96%	-23.24%	-2.72%	-29.81%	4.69%
Return on Equity Simple (ROE_SIMPLE)	-21.08%	0.00%	-20.05%	-11.78%	-10.73%	0.00%	-35.04%	-34.70%	-22.90%	0.00%	-14.89%
Net Operating Profit after Tax (NOPAT)	388	-20	-36	-3.50	-153	695	409	-458	-9.10	-668	149
NOPAT Margin	9.98%	-0.48%	-0.82%	-0.08%	-4.00%	15.60%	10.62%	-11.81%	-0.25%	-17.20%	4.14%
Net Nonoperating Expense Percent (NNEP)	1.11%	1.71%	2.11%	5.03%	1.51%	1.31%	1.81%	2.36%	1.24%	3.46%	0.45%
Return On Investment Capital (ROIC_SIMPLE)	1.69%	-0.09%	-	-	-	2.49%	-	-	-	-2.24%	-
Cost of Revenue to Revenue	51.76%	49.89%	50.39%	51.39%	53.63%	45.77%	51.92%	53.69%	56.79%	54.42%	53.57%
SG&A Expenses to Revenue	7.63%	7.14%	6.88%	6.80%	7.28%	6.53%	6.96%	7.92%	8.09%	7.42%	7.87%
R&D to Revenue	6.35%	5.84%	5.54%	6.46%	6.34%	5.07%	6.57%	6.19%	6.39%	5.41%	4.87%
Operating Expenses to Revenue	34.85%	50.84%	50.74%	48.75%	52.06%	37.29%	39.12%	63.18%	43.57%	70.10%	34.77%
Earnings before Interest and Taxes (EBIT)	294	-247	-323	-246	-468	506	65	-922	-273	-1,199	167
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	538	22	-64	13	-196	772	348	-622	31	-893	488
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.78	4.65	3.37	2.89	2.17	1.56	1.65	1.20	1.25	1.30	1.02
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.05	1.51	1.22	1.13	0.99	0.74	0.75	0.56	0.66	0.68	0.59
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.64	2.08	1.63	1.51	1.34	1.17	1.18	1.06	1.07	1.09	1.01
Enterprise Value to Revenue (EV/Rev)	1.95	2.41	2.17	2.15	2.05	1.83	1.95	1.80	1.95	1.97	1.90
Enterprise Value to EBITDA (EV/EBITDA)	63.63	0.00	69.32	37.35	108.39	54.69	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	106.61	0.00	108.09	57.00	205.11	95.45	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	25.58	31.92	19.61	29.96	23.57	21.15	25.70	15.99	19.50	18.45	26.80
Enterprise Value to Free Cash Flow (EV/FCFF)	6.58	7.47	11.15	11.50	11.20	11.00	12.07	8.13	10.45	8.23	7.63
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.66	3.11	2.97	2.84	2.60	2.44	2.66	2.68	2.40	2.47	2.23
Long-Term Debt to Equity	2.59	2.80	2.57	2.52	2.20	2.23	2.46	2.43	2.28	2.22	1.94
Financial Leverage	2.20	2.16	2.41	2.43	2.19	2.09	2.16	2.16	2.08	1.98	1.94
Leverage Ratio	5.88	5.98	6.03	5.92	5.34	5.23	5.07	5.08	4.80	4.62	4.39
Compound Leverage Factor	5.88	5.98	6.05	5.92	5.33	5.23	5.07	5.08	4.78	4.62	4.37
Debt to Total Capital	72.65%	75.66%	74.83%	73.96%	72.26%	70.94%	72.67%	72.85%	70.61%	71.16%	69.08%
Short-Term Debt to Total Capital	1.84%	7.58%	10.17%	8.31%	11.26%	5.98%	5.38%	6.98%	3.49%	7.07%	8.99%
Long-Term Debt to Total Capital	70.81%	68.08%	64.66%	65.65%	61.00%	64.96%	67.29%	65.87%	67.12%	64.08%	60.08%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.03%	1.48%	1.26%	0.81%	0.97%	2.22%	2.12%	2.31%	2.56%	2.66%	2.44%
Common Equity to Total Capital	27.32%	22.86%	23.91%	25.23%	26.77%	26.84%	25.21%	24.84%	26.83%	26.18%	28.48%
Debt to EBITDA	32.71	-79.04	36.15	19.89	65.05	37.49	-17.58	-20.76	-17.59	-11.44	-26.00
Net Debt to EBITDA	29.38	-64.37	29.83	17.48	55.14	31.39	-15.60	-18.08	-15.77	-9.93	-23.28
Long-Term Debt to EBITDA	31.89	-71.12	31.24	17.66	54.91	34.33	-16.28	-18.77	-16.72	-10.30	-22.61
Debt to NOPAT	54.81	-83.84	56.37	30.36	123.08	65.43	-22.36	-24.58	-19.75	-13.79	-26.05
Net Debt to NOPAT	49.22	-68.28	46.51	26.69	104.34	54.79	-19.84	-21.40	-17.70	-11.97	-23.33
Long-Term Debt to NOPAT	53.42	-75.45	48.71	26.95	103.91	59.92	-20.71	-22.22	-18.77	-12.42	-22.66
Altman Z-Score	0.25	0.30	0.18	0.16	0.12	0.17	0.11	-0.03	0.10	0.02	0.14
Noncontrolling Interest Sharing Ratio	1.97%	6.99%	6.48%	6.04%	6.29%	8.46%	7.83%	8.26%	8.83%	8.87%	8.27%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.03	0.98	0.89	0.89	0.89	1.02	1.00	1.02	1.10	1.05	0.99
Quick Ratio	0.46	0.50	0.49	0.46	0.47	0.54	0.49	0.52	0.54	0.57	0.52
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	5,008	5,522	2,891	2,425	2,611	3,021	3,766	3,717	3,827	4,435	4,733
Operating Cash Flow to CapEx	-82.68%	445.74%	468.24%	106.19%	-100.00%	994.96%	3.36%	272.27%	-104.32%	685.21%	445.08%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.41	0.40	0.40	0.39	0.37	0.36	0.35	0.34	0.33	0.33	0.33
Accounts Receivable Turnover	4.86	5.12	4.90	4.46	4.64	4.46	4.29	3.75	3.88	3.63	3.89
Inventory Turnover	2.35	2.41	2.10	2.05	2.03	2.09	2.09	2.01	2.00	2.08	1.97
Fixed Asset Turnover	3.24	3.20	2.97	2.89	2.82	2.76	2.73	2.62	2.56	2.55	2.61
Accounts Payable Turnover	3.57	3.53	3.62	3.38	3.39	3.65	4.23	3.72	3.93	4.45	5.01
Days Sales Outstanding (DSO)	75.13	71.34	74.50	81.84	78.58	81.82	85.02	97.34	94.01	100.57	93.73
Days Inventory Outstanding (DIO)	155.47	151.23	173.80	178.26	180.22	174.80	174.49	181.57	182.95	175.59	185.67
Days Payable Outstanding (DPO)	102.17	103.40	100.92	108.12	107.68	99.91	86.36	98.13	92.96	82.00	72.85
Cash Conversion Cycle (CCC)	128.43	119.17	147.39	151.98	151.12	156.71	173.15	180.78	184.00	194.16	206.55
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	19,767	19,131	22,261	23,233	24,387	24,673	25,188	25,661	27,151	26,999	28,545
Invested Capital Turnover	0.75	0.76	0.71	0.67	0.62	0.61	0.57	0.54	0.51	0.51	0.49
Increase / (Decrease) in Invested Capital	-4,620	-5,542	-2,927	-2,428	-2,764	-2,326	-3,357	-4,175	-3,836	-5,103	-4,584
Enterprise Value (EV)	32,388	39,802	36,395	34,992	32,735	28,930	29,738	27,102	29,130	29,334	28,754
Market Capitalization	17,427	24,972	20,415	18,405	15,817	11,703	11,431	8,437	9,831	10,129	8,962
Book Value per Share	$5.52	$4.74	$5.35	$5.61	$6.48	$6.70	$6.18	$6.29	$7.08	$7.03	$7.90
Tangible Book Value per Share	($11.82)	($12.53)	($13.08)	($13.23)	($13.17)	($13.43)	($13.81)	($14.11)	($14.31)	($14.50)	($14.46)
Total Capital	22,920	23,503	25,363	25,204	27,187	27,959	27,486	28,386	29,303	29,810	30,785
Total Debt	16,651	17,783	18,980	18,641	19,644	19,833	19,974	20,678	20,691	21,212	21,266
Total Long-Term Debt	16,230	16,002	16,400	16,547	16,584	18,161	18,495	18,698	19,668	19,103	18,497
Net Debt	14,954	14,483	15,661	16,383	16,653	16,607	17,725	18,009	18,548	18,411	19,041
Capital Expenditures (CapEx)	127	129	148	97	124	119	149	119	139	142	122
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-905	-1,763	-2,222	-1,569	-1,426	-1,316	-739	-444	-30	-110	463
Debt-free Net Working Capital (DFNWC)	792	1,537	1,097	689	1,565	1,910	1,510	2,225	2,113	2,691	2,688
Net Working Capital (NWC)	371	-244	-1,483	-1,405	-1,495	238	31	245	1,090	582	-81
Net Nonoperating Expense (NNE)	168	256	354	871	266	228	332	448	244	678	91
Net Nonoperating Obligations (NNO)	13,498	13,411	15,878	16,670	16,844	16,547	17,676	17,953	18,539	18,401	19,026
Total Depreciation and Amortization (D&A)	244	269	259	259	272	266	283	300	304	306	321
Debt-free, Cash-free Net Working Capital to Revenue	-5.45%	-10.66%	-13.25%	-9.63%	-8.91%	-8.30%	-4.84%	-2.96%	-0.20%	-0.74%	3.06%
Debt-free Net Working Capital to Revenue	4.77%	9.29%	6.54%	4.23%	9.78%	12.05%	9.89%	14.82%	14.16%	18.03%	17.75%
Net Working Capital to Revenue	2.23%	-1.47%	-8.84%	-8.62%	-9.34%	1.50%	0.20%	1.63%	7.30%	3.90%	-0.54%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.19	($0.19)	($0.39)	($0.75)	($0.12)	$0.42	$0.07	($0.77)	($0.18)	($1.18)	$0.05
Adjusted Weighted Average Basic Shares Outstanding	1.14B	1.13B	1.13B	1.13B	1.12B	1.12B	1.12B	1.12B	1.12B	1.11B	1.11B
Adjusted Diluted Earnings per Share	$0.18	($0.19)	($0.39)	($0.75)	($0.12)	$0.42	$0.07	($0.77)	($0.18)	($1.18)	$0.05
Adjusted Weighted Average Diluted Shares Outstanding	1.16B	1.13B	1.13B	1.13B	1.12B	1.12B	1.14B	1.12B	1.12B	1.11B	1.12B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.15B	1.13B	1.13B	1.13B	1.13B	1.12B	1.12B	1.12B	1.12B	1.11B	1.11B
Normalized Net Operating Profit after Tax (NOPAT)	527	639	703	573	449	731	534	475	356	519	472
Normalized NOPAT Margin	13.54%	15.11%	16.22%	13.77%	11.75%	16.41%	13.87%	12.26%	9.71%	13.36%	13.12%
Pre Tax Income Margin	7.56%	-5.84%	-7.48%	-5.91%	-12.23%	11.35%	1.69%	-23.80%	-7.43%	-30.85%	4.62%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-25.76%	-3.98%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-25.76%	-3.98%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Teva Pharmaceutical Industries' Financials

When does Teva Pharmaceutical Industries's financial year end?

According to the most recent income statement we have on file, Teva Pharmaceutical Industries' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Teva Pharmaceutical Industries' net income changed over the last 9 years?

Teva Pharmaceutical Industries' net income appears to be on a downward trend, with a most recent value of -$1.96 billion in 2024, falling from $1.60 billion in 2015. The previous period was -$615 million in 2023. Find out what analysts predict for Teva Pharmaceutical Industries in the coming months.

What is Teva Pharmaceutical Industries's operating income?

Teva Pharmaceutical Industries's total operating income in 2024 was -$303 million, based on the following breakdown:

Total Gross Profit: $8.06 billion
Total Operating Expenses: $8.37 billion

How has Teva Pharmaceutical Industries revenue changed over the last 9 years?

Over the last 9 years, Teva Pharmaceutical Industries' total revenue changed from $19.65 billion in 2015 to $16.54 billion in 2024, a change of -15.8%.

How much debt does Teva Pharmaceutical Industries have?

Teva Pharmaceutical Industries' total liabilities were at $33.61 billion at the end of 2024, a 4.9% decrease from 2023, and a 38.3% increase since 2015.

How much cash does Teva Pharmaceutical Industries have?

In the past 9 years, Teva Pharmaceutical Industries' cash and equivalents has ranged from $963 million in 2017 to $6.95 billion in 2015, and is currently $3.30 billion as of their latest financial filing in 2024.

How has Teva Pharmaceutical Industries' book value per share changed over the last 9 years?

Over the last 9 years, Teva Pharmaceutical Industries' book value per share changed from 27.68 in 2015 to 4.74 in 2024, a change of -82.9%.

Related Companies

This page (NYSE:TEVA) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Teva Pharmaceutical Industries (TEVA) Financials

Frequently Asked Questions About Teva Pharmaceutical Industries' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Teva Pharmaceutical Industries (TEVA) Financials

Annual Income Statements for Teva Pharmaceutical Industries

Quarterly Income Statements for Teva Pharmaceutical Industries

Annual Cash Flow Statements for Teva Pharmaceutical Industries

Quarterly Cash Flow Statements for Teva Pharmaceutical Industries

Annual Balance Sheets for Teva Pharmaceutical Industries

Quarterly Balance Sheets for Teva Pharmaceutical Industries

Annual Metrics And Ratios for Teva Pharmaceutical Industries

Quarterly Metrics And Ratios for Teva Pharmaceutical Industries

Frequently Asked Questions About Teva Pharmaceutical Industries' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools